JP2019532095A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532095A5 JP2019532095A5 JP2019531514A JP2019531514A JP2019532095A5 JP 2019532095 A5 JP2019532095 A5 JP 2019532095A5 JP 2019531514 A JP2019531514 A JP 2019531514A JP 2019531514 A JP2019531514 A JP 2019531514A JP 2019532095 A5 JP2019532095 A5 JP 2019532095A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- ophthalmic preparation
- preparation according
- compound
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 21
- -1 azole compound Chemical class 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000029515 lens disease Diseases 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000003851 azoles Chemical class 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 229940058690 lanosterol Drugs 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 231100000344 non-irritating Toxicity 0.000 claims 1
- 239000002997 ophthalmic solution Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 201000010041 presbyopia Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610717956.2A CN107397745A (zh) | 2016-08-24 | 2016-08-24 | 唑类化合物眼用制剂 |
| CN201610717956.2 | 2016-08-24 | ||
| PCT/CN2017/098662 WO2018036523A1 (zh) | 2016-08-24 | 2017-08-23 | 唑类化合物眼用制剂 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532095A JP2019532095A (ja) | 2019-11-07 |
| JP2019532095A5 true JP2019532095A5 (https=) | 2020-03-19 |
| JP6890794B2 JP6890794B2 (ja) | 2021-06-18 |
Family
ID=60389600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531514A Expired - Fee Related JP6890794B2 (ja) | 2016-08-24 | 2017-08-23 | アゾール系化合物の眼用製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190192427A1 (https=) |
| EP (1) | EP3505170B1 (https=) |
| JP (1) | JP6890794B2 (https=) |
| KR (1) | KR20190052005A (https=) |
| CN (2) | CN107397745A (https=) |
| AU (1) | AU2017317154B2 (https=) |
| CA (1) | CA3034766A1 (https=) |
| EA (1) | EA201990550A1 (https=) |
| SG (1) | SG11201901617PA (https=) |
| WO (1) | WO2018036523A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109985071A (zh) * | 2017-12-29 | 2019-07-09 | 上海蓝木化工有限公司 | 桦褐孔菌提取物的新用途 |
| EP4349327A3 (en) * | 2018-08-28 | 2024-07-24 | Cloudbreak Therapeutics, LLC | Emulsion formulations of multikinase inhibitors |
| MX2021009520A (es) * | 2021-08-06 | 2023-02-07 | Foodvica S A De C V | Composicion oftalmica para el tratamiento de trastornos visuales. |
| CN115737654B (zh) * | 2021-09-03 | 2025-11-21 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药预防和/或治疗白内障的眼用制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02290815A (ja) * | 1989-05-01 | 1990-11-30 | Santen Pharmaceut Co Ltd | 抗真菌点眼剤 |
| WO1999063968A1 (fr) * | 1998-06-10 | 1999-12-16 | Wakamoto Pharmaceutical Co., Ltd. | Preparations aqueuses contenant des medicaments faiblement solubles |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| CN100418536C (zh) * | 2005-04-06 | 2008-09-17 | 河南省眼科研究所 | 一种用于眼科的抗真菌药物组合物 |
| CN100418530C (zh) * | 2005-04-06 | 2008-09-17 | 河南省眼科研究所 | 一种酮康唑滴眼液及其制造方法 |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| JP2011505409A (ja) * | 2007-12-04 | 2011-02-24 | ノバガリ ファーマ エスエー | パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物 |
| CN101766628B (zh) * | 2010-01-20 | 2012-07-04 | 广东宏盈科技有限公司 | 一种眼科外用抗细菌感染药物 |
| CN101786993A (zh) * | 2010-03-26 | 2010-07-28 | 复旦大学 | 1，2，3-三氮唑化合物及其在制备吲哚胺2，3-双加氧酶抑制剂中的用途 |
| CN104027302B (zh) * | 2013-03-07 | 2019-04-05 | 中国医药工业研究总院 | 17α-乙炔基雄甾-5-烯-3β,7β,17β-三醇眼用制剂 |
| JP2015093869A (ja) * | 2013-11-14 | 2015-05-18 | 国立大学法人東北大学 | 網膜保護薬剤、及び網膜疾患治療用徐放デバイス |
| CN103736093A (zh) * | 2013-12-27 | 2014-04-23 | 于运红 | 一种包含咪唑斯汀及甾族化合物的药物制剂 |
| WO2016029197A1 (en) * | 2014-08-22 | 2016-02-25 | Kang Zhang | Compositions and methods to treat and/or prevent vision disorders of the lens of the eye |
| KR20170048426A (ko) * | 2014-08-22 | 2017-05-08 | 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. | 시각 장애를 치료하기 위한 조성물 및 방법 |
-
2016
- 2016-08-24 CN CN201610717956.2A patent/CN107397745A/zh active Pending
-
2017
- 2017-08-23 WO PCT/CN2017/098662 patent/WO2018036523A1/zh not_active Ceased
- 2017-08-23 EP EP17842945.2A patent/EP3505170B1/en active Active
- 2017-08-23 CN CN201780051907.2A patent/CN109689049B/zh active Active
- 2017-08-23 JP JP2019531514A patent/JP6890794B2/ja not_active Expired - Fee Related
- 2017-08-23 CA CA3034766A patent/CA3034766A1/en not_active Abandoned
- 2017-08-23 SG SG11201901617PA patent/SG11201901617PA/en unknown
- 2017-08-23 EA EA201990550A patent/EA201990550A1/ru unknown
- 2017-08-23 AU AU2017317154A patent/AU2017317154B2/en not_active Ceased
- 2017-08-23 KR KR1020197008376A patent/KR20190052005A/ko not_active Withdrawn
- 2017-08-23 US US16/327,238 patent/US20190192427A1/en not_active Abandoned
-
2021
- 2021-07-06 US US17/367,863 patent/US20210330586A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7569336B2 (ja) | マイクロエマルション組成物 | |
| JP6209777B2 (ja) | 眼の疾病及び疾患のための組成物及び治療 | |
| KR101809713B1 (ko) | 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템 | |
| ES2386786T3 (es) | Método para tratar rubor cutáneo usando agonistas selectivos de receptores alpha-2-adrenérgicos. | |
| JP2008520671A (ja) | 眼科用組成物および眼の治療方法 | |
| US8633181B2 (en) | Treatment of cutaneous hemangioma | |
| JP2019532095A5 (https=) | ||
| AU2008325214A1 (en) | Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor | |
| WO2010048788A1 (zh) | 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法 | |
| JP2018522070A (ja) | 白内障の処置用組成物 | |
| KR20200111177A (ko) | 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법 | |
| JP2017519813A (ja) | 局所製剤およびその使用 | |
| JP2025507154A (ja) | 眼の状態の治療を目的とした連続投薬レジメン | |
| JP6890794B2 (ja) | アゾール系化合物の眼用製剤 | |
| JP2017509668A (ja) | 高浸透圧ヒアルロン酸組成物 | |
| KR101433396B1 (ko) | 안구 적용용 아마인 추출물 약제 | |
| CN104721136A (zh) | 一种布佐林胺眼用纳米混悬剂及其制备方法 | |
| JP2014521606A (ja) | 眼表面アレルギーの処置のための組成物および方法 | |
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| CN102018656A (zh) | 含有效成分拉坦前列素的眼用凝胶剂及其制备方法 | |
| JP4263418B2 (ja) | 熱ゲル化人工涙液 | |
| TW202345853A (zh) | 無防腐劑的眼科藥物乳劑及其應用 | |
| JPWO2020138135A1 (ja) | 眼科用組成物 | |
| RU2787998C1 (ru) | Микроэмульсионные композиции | |
| MX2011005586A (es) | Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo. |